Published January 15, 2014 | Version v1
Journal article

The inhibitory and combinative mechanism of HZ08 with P-glycoprotein expressed on the membrane of Caco-2 cell line

  • 1. State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing 210009 (China)
  • 2. Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009 (China)

Description

Recently, the research and development of agents to reverse the phenomenon of multidrug resistance has been an attractive goal as well as a key approach to elevating the clinical survival of cancer patients. Although three generations of P-glycoprotein modulators have been identified, poor clearance and metabolism render these agents too toxic to be used in clinical application. HZ08, which has been under investigation for several years, shows a dramatic reversal effect with low cytotoxicity. For the first time, we aimed to describe the interaction between HZ08 and P-glycoprotein in Caco-2 cell line in which P-glycoprotein is overexpressed naturally. Cytotoxicity and multidrug resistance reversal assays, together with flow cytometry, fluorescence microscopy and siRNA interference as well as Caco-2 monolayer transport model were employed in this study to evaluate the interaction between HZ08 and P-glycoprotein. This study revealed that HZ08 was capable of reversing adriamycin resistance mediated by P-glycoprotein as a result of intracellular enhancement of adriamycin accumulation, which was found to be superior to verapamil. In addition, we confirmed that HZ08 suppressed the transport of Rhodamine123 in the Caco-2 monolayer model but had little effect on P-glycoprotein expression. The transport of HZ08 was diminished by P-glycoprotein inhibitors (verapamil and LY335979) and its accumulation was increased via siRNA targeting MDR1 in Caco-2 cells. Furthermore, considering the binding site of P-glycoprotein, verapamil performed as a competitive inhibitor with HZ08. In conclusion, as a P-glycoprotein substrate, HZ08 inhibited P-glycoprotein activity and may share the same binding site of verapamil to P-glycoprotein. - Highlights: • The cytotoxicity and reversing effect of HZ08 was measured in Caco-2 cell line. • HZ08 inhibited the transport of Rhodamine123 across Caco-2 cell monolayer. • The efflux ratio of HZ08 was dropped when combined with P-glycoprotein inhibitors. • The accumulation of HZ08 increased via gene interference targeting P-glycoprotein. • HZ08 competitively bound to P-glycoprotein under the presence of verapamil

Availability note (English)

Available from http://dx.doi.org/10.1016/j.taap.2013.11.019

Additional details

Identifiers

DOI
10.1016/j.taap.2013.11.019;
PII
S0041-008X(13)00539-5;

Publishing Information

Journal Title
Toxicology and Applied Pharmacology
Journal Volume
274
Journal Issue
2
Journal Page Range
p. 232-239
ISSN
0041-008X
CODEN
TXAPA9

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
45107002
Subject category
S60: APPLIED LIFE SCIENCES;
Descriptors DEI
DOXORUBICIN; FLUORESCENCE; GLYCOPROTEINS; MEMBRANES; METABOLISM; NEOPLASMS; TOXICITY
Descriptors DEC
ANTIBIOTICS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC DRUGS; CARBOHYDRATES; DISEASES; DRUGS; EMISSION; LUMINESCENCE; ORGANIC COMPOUNDS; PHOTON EMISSION; PROTEINS; SACCHARIDES

Optional Information

Copyright
Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.